Tagged with Investment,

Belgium Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million patients via its locally available portfolio. 18 months into his role as Country President for BeLux, Federico Mambretti expands on…

Greece EY Greece’s George Mitropoulos outlines some of the key challenges and opportunities for both local manufacturers and multinational innovators in Greece, how EY is uniquely positioned to assist them, and the fundamentals that give him cause for optimism for both the Greek economy and its healthcare sector.   We believe…

Greece Spyridon Gkikas outlines how GE HealthCare’s global transformation is playing out in Greece as well as the opportunities and challenges of bringing cutting-edge medical technology into the Greek healthcare system.   EU Recovery and Resilience Funding (RRF) is coming online, creating an opportunity for Greece to improve its healthcare system,…

Greece Longstanding J&J Greece Managing Director Theodore Liakopoulos looks back on the progress that Greek healthcare has made in the past four years, thanks in no small part to the commitment of the multinational medtech industry. Liakopoulos highlights the importance of establishing a centralised procurement authority for the sustainability of Greek…

China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…

Belgium While only Europe’s 34th biggest country by landmass and 13th by population, Belgium punches well above its weight in terms of key life sciences industry indicators, notably placing in the Top Five European countries for pharma R&D spending, pharma exports, and pharma imports. Made with Visme Infographic Maker   Made…

Egypt Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda. What has occurred subsequently has undoubtedly been momentous. Firstly, his administration unveiled ambitious plans to provide universal, cradle to grave,…

Global David H. Crean, Managing Partner for Cardiff Advisory, highlights the tone and tenor of J.P. Morgan’s recent 2023 Healthcare Conference held in San Francisco in light of the uncertain economic environment that saw fewer IPOs in 2022 than in previous years and numerous negative enterprise value companies trading below cash…

USA Initial public offerings (IPOs) —a vital source of cash for up-and-coming biotechs— saw a huge decline in 2022 with respect to the previous year. After 2021’s record of more than 100 biotech IPOs that raised almost USD 15 billion in funds, 2022 saw a mere 17 biotechnology companies launch IPOs…

Germany Home to Europe’s largest pharma market, a host of industry giants, a thriving biotech scene, and a public healthcare system undergoing significant reform, Germany is indisputably one of the world’s most important life science nations.   An overview of the pharma industry in Germany. Made with Visme Infographic Maker   The…

LatAm Yaneth Giha of FIFARMA – the leading association for the innovative pharmaceutical industry in Latin America – gives a bird’s-eye overview on some of the key trends in LatAm healthcare, from regulatory and access challenges to the impact of the COVID-19 pandemic, the region’s potential as a clinical trials hub,…

Greece Michael Himonas of SFEE, the umbrella pharmaceutical association of 40 global innovative biopharma companies and 20 local companies in Greece, explains how the country’s pharmaceutical clawback and rebate system is restricting the growth of the industry and ultimately limiting and delaying patient access to medicines. However, Himonas is also keen…